Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Arthur L. Weaver"'
Autor:
Arthur L. Weaver, Leslie S. Fish, Robert L. Barkin, Eugene R. Viscusi, Ronald J. Kulich, Louis Kuritzky, Bill McCarberg, Bruce D. Nicholson, Joshua Rittenberg
Publikováno v:
American Journal of Therapeutics. 15:S24-S27
Publikováno v:
JCR: Journal of Clinical Rheumatology. 14:S42-S46
seems to be increasing. 1–3 Most patients visit a primary care physician (PCP) for gout disease management; however, there are a number of challenges to diagnosing and treating gout in the PCP setting. Newer investigational agents for gout that are
Autor:
Allan Gibofsky, Arthur L. Weaver, Joseph A. Markenson, Harold E. Paulus, Michael Schiff, Jonathan A Leff, John A. Goldman, James B Whitmore, Richard L Lautzenheiser, Melanie J. Harrison, Edward C. Keystone, William R Palmer
Publikováno v:
Current Medical Research and Opinion. 22:169-183
Rheumatoid Arthritis (RA) Disease-Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS) is a unique, real-world, prospective, 5-year, observational study of over 10 000 patients with RA. RADIUS provides a snapshot of use p
Autor:
Arthur L. Weaver, Gregory P. Geba, Nathaniel P. Katz, Wendy P. Battisti, Adam B. Polis, Alan J. Kivitz, Alan K. Matsumoto
Publikováno v:
The Journal of Pain. 5:511-520
We compared onset of efficacy (during days 1 to 6) of 2 coxibs (rofecoxib, celecoxib) with acetaminophen and nabumetone by using a prespecified approach to data from 4 similarly designed 6-week randomized osteoarthritis trials. In 2 trials, rofecoxib
Autor:
Ted R. Mikuls, Arthur L. Weaver
Publikováno v:
Current Rheumatology Reports. 5:270-277
Tumor necrosis factor-alpha (TNFa) plays a central role in rheumatoid arthritis (RA) pathogenesis. There are currently three available anti-TNFa agents for the treatment of RA--adalimumab, etanercept, and infliximab. These targeted therapies have sel
Autor:
Louis Kuritzky, Arthur L. Weaver
Publikováno v:
Journal of Pain and Symptom Management. 25:6-20
Arthritis is a growing health concern in the US with approximately 70 million Americans currently affected. This figure will inevitably rise as the population ages. The pain and decreased mobility associated with arthritis have a significant impact o
Autor:
Arthur L. Weaver
Publikováno v:
Journal of Pain and Symptom Management. 23:S31-S34
In your opinion, are the recommendations for use of acetaminophen as first-line treatment for the pain of osteoarthritis (OA) based on well-established clinical trials? Dr. Weaver: This statement is probably more true than false. The tremendous impet
Autor:
Nancy J. Olsen, Vibeke Strand, Larry W. Moreland, Jeffrey L. Kaine, Stanley Cohen, Jacques Caldwell, Robert I. Fox, Daniel E. Furst, Michael Schiff, Arthur L. Weaver, Grant W. Cannon, John T. Sharp
Publikováno v:
Arthritis & Rheumatism. 44:1984-1992
Objective Three 6-12-month, double-blind, randomized, controlled trials have shown leflunomide (LEF; 20 mg/day, loading dose 100 mg x 3 days) to be effective and safe for the treatment of rheumatoid arthritis (RA). This analysis of the North American
Autor:
Lynell Warren Klassen, Gail Paulsen, Steven Wees, Gerald Francis Moore, Deborah K. Doud, Arthur L. Weaver, Melvin Churchill, P. James Eckhoff, James R. O'Dell, Kent Blakely, William E. Palmer, Claire E. Haire
Publikováno v:
Arthritis & Rheumatism. 42:1691-1695
Objective. Rheumatoid arthritis (RA) causes substantial morbidity and mortality, and current treatments are suboptimal. Recent studies have demonstrated the short-term efficacy of minocycline in the treatment of patients with early RA. This study was
Autor:
Jacques Caldwell, Larry Hancock, Steven Hurley, Shobha Dhadda, Alan J. Kivitz, Tomas S. Bocanegra, Julie Ball, Arthur L. Weaver, Naurang M. Agrawal
Publikováno v:
Clinical Therapeutics. 21:659-674
A 6-week, multicenter, double-masked, placebo-controlled, paralle1-group study compared the upper gastrointestinal (UGI) safety of Arthrotec ® 75 (diclofenac sodium 75 mg-misoprostol 200 μg; G.D. Searle & Co., Skokie, Illinois) administered twice d